The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

reveal that patients undergoing surgery for localized muscle-invasive bladder cancer gain no significant survival advantage from extended lymph node removal (extended lymphadenectomy) compared to ...

Removing more lymph nodes during surgery may also increase the risk for death after surgery in muscle-invasive bladder cancer ...

Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...

Opens in a new tab or window A personalized strategy of dose-escalated radiotherapy (RT) for bladder cancer had a low rate of severe late toxicity and survival comparable to historical results ...

The following is a summary of “Identification and experimental validation of a sialylation–related long noncoding RNA ...

Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory ...

Event-free survival rates at 12 months were 67.8% ... This trial suggests a new treatment option for patients with muscle-invasive bladder cancer; future work should evaluate the relative efficacy ...

In this randomized controlled trial, extended lymphadenectomy did not improve disease-free or overall survival in patients ...

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher ...

phase 3 trial of extended or standard pelvic lymphadenectomy during radical cystectomy in patients with muscle-invasive bladder cancer. Our primary objective was to compare disease-free survival ...

Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients ...